Activation of the IL-3- or GM-CSF-induced JAK2-STAT5 signaling pathway is necessary to establish mTORC1 activity, which is required for IFN-I production by pDCs at nephrotic sites in patients with SLE [216]. Here, IL3 is linked to systemic lupus erythematosus.